DF
BEAM icon

Dunhill Financial’s Beam Therapeutics BEAM Stock Holding History

Dunhill Financial’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6K Hold
75
– – ﹤0.01% 789
2026
Q1 		$1.8K Sell
75
-1
-1% -$28 ﹤0.01% 830
2025
Q4 		$2.1K Buy
76
+2
+3% +$51 ﹤0.01% 731
2025
Q3 		$1.8K Hold
74
– – ﹤0.01% 709
2025
Q2 		$1.26K Hold
74
– – ﹤0.01% 747
2025
Q1 		$1.45K Hold
74
– – ﹤0.01% 782
2024
Q4 		$1.83K Hold
74
– – ﹤0.01% 717
2024
Q3 		$1.81K Hold
74
– – ﹤0.01% 732
2024
Q2 		$1.73K Hold
74
– – ﹤0.01% 590
2024
Q1 		$2.44K Hold
74
– – ﹤0.01% 452
2023
Q4 		$2.01K Buy
+74
New +$1.84K ﹤0.01% 455

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Dunhill Financial's BEAM Position: Q2 2026 in Review

Dunhill Financial held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 75 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Dunhill Financial first reported a position in BEAM in Q4 2023 and has held it in 11 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Dunhill Financial held 75 shares of Beam Therapeutics worth $2.6K as of Q2 2026.
  • Dunhill Financial left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #789 holding.
  • Dunhill Financial first reported a position in Beam Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.